This week on "The Readout LOUD" podcast: an AI experiment at the FDA and how Novo Nordisk is trailing in the obesity drug ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

DEPARTMENT OF JUSTICE NEWS RELEASE Attorney General Raúl Torrez announced settlements with two major insulin ...

The attorney general described the agreements as "huge wins" for New Mexico, which is home to more than 200,000 adults with ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

This article summarizes recent developments in the health sector, including major acquisitions, drug trial results, and ...

In settlements, two insulin manufacturers committed to selling insulin to New Mexicans for $35 or less per month.

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target of €100.00. Confident Inves ...

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual agreement." ...